ZEO ScientifiX, Inc.
Clinical-stage biopharmaceutical company focused on research, development, and cGMP-compliant manufacturing of regenerative biologics. Operates FDA-registered cGMP laboratory and manufacturing facilities on an academic research campus with imaging, animal research, and genomic core capabilities. Activities include preclinical research, early-phase clinical studies, physician-directed education on regulatory compliance, and contract manufacturing and supply of perinatal-derived and autologous extracellular vesicle (EV) therapeutics for investigational and clinical use.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Products
Cryopreserved umbilical cord-derived cellular products
Clinical-grade umbilical cord-derived cellular products supplied with defined live-cell counts, cryopreserved for on-demand clinical use and accompanied by certificates of analysis and viability metrics.
Extracellular vesicle-enriched Wharton's jelly scaffold
Collagen- and hyaluronic-rich matrix derived from Wharton's jelly combined with concentrated extracellular vesicle payload for tissue repair and regenerative adjunct applications.
Amniotic membrane sheets and patches
Extracellular membrane sheets and discs retaining endogenous growth factors and collagen networks for surgical closure and chronic wound management.
Autologous platelet-derived extracellular vesicle concentrates
Patient-derived platelet fractions processed via sequential centrifugation to concentrate EVs/nanoparticles; preparations produced in a cGMP facility and released with sterility and nanoparticle-count documentation for autologous clinical procedures.
Amniotic fluid-derived extracellular vesicle biologics
Acellular EV preparations sourced from amniotic fluid intended for investigational anti-inflammatory and regenerative applications with supporting preclinical and clinical publications.
Topical EV-enriched formulations for hair and aesthetic applications
Collaborative topical formulations combining extracellular vesicle payloads and complementary ingredients for hair growth and aesthetic use in physician-led settings.
Cryopreserved umbilical cord-derived cellular products
Clinical-grade umbilical cord-derived cellular products supplied with defined live-cell counts, cryopreserved for on-demand clinical use and accompanied by certificates of analysis and viability metrics.
Extracellular vesicle-enriched Wharton's jelly scaffold
Collagen- and hyaluronic-rich matrix derived from Wharton's jelly combined with concentrated extracellular vesicle payload for tissue repair and regenerative adjunct applications.
Amniotic membrane sheets and patches
Extracellular membrane sheets and discs retaining endogenous growth factors and collagen networks for surgical closure and chronic wound management.
Autologous platelet-derived extracellular vesicle concentrates
Patient-derived platelet fractions processed via sequential centrifugation to concentrate EVs/nanoparticles; preparations produced in a cGMP facility and released with sterility and nanoparticle-count documentation for autologous clinical procedures.
Amniotic fluid-derived extracellular vesicle biologics
Acellular EV preparations sourced from amniotic fluid intended for investigational anti-inflammatory and regenerative applications with supporting preclinical and clinical publications.
Topical EV-enriched formulations for hair and aesthetic applications
Collaborative topical formulations combining extracellular vesicle payloads and complementary ingredients for hair growth and aesthetic use in physician-led settings.
Services
Multi-hour in-person training for licensed physicians covering statutory requirements, sourcing and consent standards, scientific foundations of biologic therapies, clinical integration, and operational best practices.
Clinical-grade manufacturing, quality release, and supply of perinatal-derived and autologous biologic products for investigational and regulated clinical use under established quality systems.
Design and execution support for IRB-approved studies and early-phase clinical research, including investigator-led trials and collaborative data collection aligned with regulatory expectations.
Consulting on operational models, economic planning, compliance procedures, and supplier/fulfillment pathways to integrate biologic therapies into clinical practice.
Multi-hour in-person training for licensed physicians covering statutory requirements, sourcing and consent standards, scientific foundations of biologic therapies, clinical integration, and operational best practices.
Clinical-grade manufacturing, quality release, and supply of perinatal-derived and autologous biologic products for investigational and regulated clinical use under established quality systems.
Design and execution support for IRB-approved studies and early-phase clinical research, including investigator-led trials and collaborative data collection aligned with regulatory expectations.
Consulting on operational models, economic planning, compliance procedures, and supplier/fulfillment pathways to integrate biologic therapies into clinical practice.
Expertise Areas
- Regenerative biologics manufacturing
- Extracellular vesicle and nanoparticle therapeutics
- Perinatal-derived biologic materials and processing
- Early-phase clinical research and IND/Phase II planning
Key Technologies
- Extracellular vesicle and exosome isolation
- Perinatal tissue-derived biologics
- Autologous platelet nanoparticle concentration
- cGMP manufacturing and ISO7 cleanroom operations
News & Updates
Announcement of an educational Masterclass for physicians to explain Florida's SB-1768 sourcing and compliance requirements and clinical integration of non-FDA-approved stem cell and EV therapies.
Discussion of Florida's law permitting certain non-FDA-approved stem cell therapies under regulated conditions, and implications for supplier sourcing, informed consent, and clinical practice.
Press release describing a strategic collaboration to coordinate manufacturing, regulatory development, and U.S. commercialization pathways for an allogeneic stem cell therapy with CDMO and commercial partners.
Corporate update summarizing completion of Phase I safety trials for a perinatal-derived EV therapeutic, growth in an autologous nanoparticle product line, patent issuances for processing techniques, and educational and commercialization initiatives.
Press release describing a memorandum of understanding to position the company as a biologics supplier integrated into a telemedicine and clinic network including prescriber and pharmacy fulfillment.
Announcement of selection as a Qualified Team advancing EV/exosome therapeutics and delivery systems into controlled clinical evaluation in a global competition.
Announcement of an educational Masterclass for physicians to explain Florida's SB-1768 sourcing and compliance requirements and clinical integration of non-FDA-approved stem cell and EV therapies.
Discussion of Florida's law permitting certain non-FDA-approved stem cell therapies under regulated conditions, and implications for supplier sourcing, informed consent, and clinical practice.
Press release describing a strategic collaboration to coordinate manufacturing, regulatory development, and U.S. commercialization pathways for an allogeneic stem cell therapy with CDMO and commercial partners.
Corporate update summarizing completion of Phase I safety trials for a perinatal-derived EV therapeutic, growth in an autologous nanoparticle product line, patent issuances for processing techniques, and educational and commercialization initiatives.
Press release describing a memorandum of understanding to position the company as a biologics supplier integrated into a telemedicine and clinic network including prescriber and pharmacy fulfillment.
Announcement of selection as a Qualified Team advancing EV/exosome therapeutics and delivery systems into controlled clinical evaluation in a global competition.